Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand the disease better and in the future may help to find new treatments. Research directions on MS treatments include investigations of MS pathogenesis and heterogeneity; research of more effective, convenient, or tolerable new treatments for RRMS; creation of therapies for the progressive subtypes; neuroprotection strategies; and the search for effective symptomatic treatments.
Separated variants Several previous MS variants have been recently separated from MS after the discovery of a specific auto-antibody, specially autoantibodies against AQP4, MOG and Neurofascin proteins. Previously recognized variants of MS like Optic-Spinal MS is now classified as a phenotype of the anti-AQP4 spectrum, and some tumefactive cases of MS as anti-MOG associated encephalomyelitis. Some researchers think that there could exist also an overlapping between Anti-NMDA receptor encephalitis cases and neuromyelitis optica or acute disseminated encephalomyelitis. The following previous MS variants are now considered apart from MS:
Optic-Spinal MS: Now it is considered inside the Anti-AQP4 diseases spectrum. Anti-MOG associated MS and some cases of tumefactive multiple sclerosis currently considered inside the anti-MOG spectrum. Anti-neurofascin associated MS and CIDP: Some Anti-neurofascin demyelinating diseases were previously considered a subtype of Multiple Sclerosis but now they are considered a separate entity, as it happened before to anti-MOG and anti-AQP4 cases. Around 10% of MS cases are now thought to be anti-Neurofascin disease in reality. Anti-neurofascin autoantibodies have been reported in atypical cases of MS and CIDP, and a whole spectrum of Anti-neurofascin demyelinating diseases has been proposed. Some cases of CIDP are reported to be produced by auto-antibodies against several neurofascin proteins. These proteins are present in the neurons and four of them have been reported to produce disease: NF186, NF180, NF166 and NF155. Antibodies against Neurofascins NF-155 can also appear in MS and NF-186 could be involved in subtypes of MS yielding an intersection between both conditions. Summarising, autoantibodies against several neurofascins can produce MS: neurofascin186 (NF186), neurofascin155 (NF155), contactin 1 (CNTN1), contactin associated protein 1 (CASPR1) and gliomedin. All of them nodal and paranodal proteins. Anti-TNF associated MS: Several anti-TNF drugs like adalimumab are commonly prescribed by a number of autoimmune conditions. Some of them have been reported to produce a CNS-demyelination compatible with, and by current knowledge indistinguishable from, standard MS. Several other monoclonal antibodies like pembrolizumab, nivolumab and infliximab have been also reported to produce MS artificially. This has given birth to the Anti-TNF-α therapy-associated demyelinating disorders. The reactions have been diverse according to the source of the disease. Some of these cases can be classify as ADEM, using the confluent demyelination as barrier between both conditions. In most cases, the damage fulfills all pathological diagnostic criteria of MS and can therefore be classified as MS in its own right. The lesions were classified as pattern II in the Lassman/Lucchinetti system. Some lesions also showed Dawson fingers, which is supposed to be a MS-only feature. LHON-associated MS: Also a previous subtype of MS associated to LHON has been described (LHON-MS). It is a presentation of LHON with MS-like CNS damage. It used to satisfy McDonalds definition for MS, but after demonstration that LHON can produce this kind of lesions, the "no better explanation" requirement does not hold anymore. It is not due to auto-antibodies, but to defective mitochondria instead. The symptoms of this higher form of the disease include loss of the brain's ability to control the movement of muscles, tremors, and cardiac arrhythmia. and the lack of muscular control.
… excerpt ends here. Continue reading the full article.
